Compare BioNano Genomics Inc (BNGO) vs General Mills, Inc. (GIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs General Mills, Inc. — how do they compare? BioNano Genomics Inc trades at $1.18 (market cap $13.66M), while General Mills, Inc. trades at $38.11 (market cap $20.24B). The key difference: General Mills, Inc. is far larger — about 1481.7× BioNano Genomics Inc's market cap, and General Mills, Inc. pays a 6.43% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | GIS | |
|---|---|---|
Market Cap | $13.66M | $20.24B |
Sector | Health | Consumer Staples |
52-Week High | $4.92 | $51.11 |
52-Week Low | $1.06 | $32.17 |
Enterprise Value | $16.26M | $33.73B |
Dividend Yield | — | 6.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.195, up 3.02% today, with a bullish technical signal from moving averages but a neutral oscillator stance. The company shows improving financial trends, with net losses narrowing to -$26.40M in 2025 from -$232M in 2023, and recent earnings beats. Revenue stabilized around $29M, while cash flow trends indicate reduced operational cash burn. Analyst sentiment is positive, with 57% buy ratings.
The outlook for BNGO hinges on sustaining revenue growth and achieving profitability, supported by strategic hires and debt retirement. Key risks include persistent negative margins and high cash burn. With a low P/S of 0.31, the stock offers value if execution improves, but investors face volatility from operational challenges and competitive pressures.
General Mills (GIS) trades at $38.21, up 2.55% today, with a bullish technical signal from moving averages but mixed oscillators. Recent earnings show volatility, beating estimates in Q3 2025 and Q2 2026 but missing in Q4 2025. Revenue has declined from $20.1B in 2023 to $19.5B in 2025, with net income margin turning negative at -0.48% for 2026. The company maintains a dividend and is pursuing cost savings initiatives, while debt-to-asset ratio has risen to 45% in 2025.
Outlook is cautious; the stock offers a low P/E of 9.23 and dividend income, but faces headwinds from weak sales, margin pressure, and high debt. Analyst consensus is mixed with 22% buy, 61% hold ratings. Key risks include competitive pressures and execution of turnaround plans. Investors should weigh valuation appeal against fundamental challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About General Mills, Inc.
General Mills is a leading global packaged food company that produces snacks, cereal, convenient meals, yogurt, dough, baking mixes and ingredients, pet food, and superpremium ice cream. Its largest brands are Nature Valley, Cheerios, Old El Paso, Yoplait, Pillsbury, Betty Crocker, BLUE, and Haagen-Dazs. In fiscal 2022, 77% of its revenue was derived from the United States, although the company also operates in Canada, Europe, Australia, Asia, and Latin America. While most of General Mills' products are sold through retail stores to consumers, the company also sells products into the food-service channel and the commercial baking industry.
Read more on GIS →
